|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,464,632: A Deep Dive into its Scope, Claims, and Patent Landscape
U.S. Patent 5,464,632, titled "Process for the preparation of 1-[4-(4-fluorophenyl)-1-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-phenylbutyl]-4-piperidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid," was granted on November 7, 1995. The patent describes a novel synthetic process for the compound now known as Risperidone, an atypical antipsychotic medication. This analysis examines the patent's core claims, its asserted scope, and the subsequent patent landscape that has emerged.
What are the Key Claims of U.S. Patent 5,464,632?
The patent's primary claims focus on a specific chemical process for synthesizing Risperidone. The most pertinent claims are:
-
Claim 1: This claim defines a specific process for preparing Risperidone. It involves the reaction of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one with 4-(4-fluorophenyl)-1-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-piperidinol. The process specifies conditions including the use of a solvent, a base, and a temperature range to achieve the desired product.
-
Claim 2: This claim depends on Claim 1 and further specifies the use of a tertiary amine base in the process.
-
Claim 3: This claim depends on Claim 1 and specifies a particular solvent system, namely dimethylformamide (DMF).
-
Claim 4: This claim depends on Claim 1 and further defines a temperature range for the reaction, typically between 50°C and 100°C.
-
Claim 5: This claim is directed to an intermediate compound used in the process described in Claim 1. Specifically, it claims 4-(4-fluorophenyl)-1-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-piperidinol.
-
Claim 6: This claim is directed to a specific salt form of Risperidone, namely the hydrochloride salt.
The patent does not claim the compound Risperidone itself as a composition of matter, as that composition was likely disclosed in prior art or other patents. Its innovation lies in the specific manufacturing route it delineates.
What is the Asserted Scope of the Patent?
The asserted scope of U.S. Patent 5,464,632 is primarily the patented process for synthesizing Risperidone. This includes:
- The specific chemical reaction steps outlined in Claim 1.
- The use of the specified intermediate compounds, particularly as claimed in Claim 5.
- The employment of particular reagents, solvents (e.g., DMF as in Claim 3), bases (e.g., tertiary amines as in Claim 2), and reaction conditions (e.g., temperature range as in Claim 4).
- The production of the hydrochloride salt form of Risperidone (Claim 6).
The patent aims to prevent other manufacturers from utilizing this precise synthetic pathway to produce Risperidone without a license. This is a common strategy in pharmaceutical patenting, where process patents are used to protect market exclusivity, especially when composition of matter patents have expired or are nearing expiration.
How Does the Patent Landscape for Risperidone Look Post-Patent 5,464,632?
The patent landscape surrounding Risperidone is complex, reflecting its significant therapeutic value and the strategic patenting employed by its innovator. U.S. Patent 5,464,632 was a critical piece of this strategy, protecting the manufacturing method.
The primary innovator of Risperidone was Janssen Pharmaceutica (part of Johnson & Johnson). U.S. Patent 5,464,632 was originally assigned to Janssen Pharmaceutica N.V. [1].
Key Developments in the Risperidone Patent Landscape:
-
Expiration of Key Patents: U.S. Patent 5,464,632 expired on November 7, 2012. This expiration opened the door for generic manufacturers to produce and market Risperidone, provided they did not infringe on other valid patents.
-
"Evergreening" Strategies: Pharmaceutical companies often employ "evergreening" strategies to extend market exclusivity. This can involve obtaining patents on new formulations, delivery systems, polymorphs, or new medical uses of an existing drug. For Risperidone, this included patents on:
- Formulations: For example, extended-release formulations or orally disintegrating tablets.
- Delivery Devices: Such as long-acting injectable formulations.
- New Indications: While Risperidone is primarily known for treating schizophrenia and bipolar disorder, new therapeutic uses might have been explored and patented.
-
Generic Competition: Following the expiration of core process and composition of matter patents, numerous generic versions of Risperidone became available. This led to a significant price decrease for the drug.
-
Litigation: The introduction of generic Risperidone has historically been accompanied by patent litigation. Generic manufacturers often challenge the validity or inventiveness of remaining patents, while innovator companies seek to enforce their intellectual property rights. Disputes can arise over whether a generic process infringes on existing process patents, even if those patents are different from U.S. Patent 5,464,632.
-
Orphan Drug Exclusivity: While Risperidone is not an orphan drug for its primary indications, specific new uses or formulations might have qualified for Orphan Drug Exclusivity, providing an additional period of market protection.
-
Post-Expiration Patent Challenges: Even after the expiration of U.S. Patent 5,464,632, other patents related to Risperidone might have remained active, influencing the market. These could include patents on specific polymorphic forms of the active pharmaceutical ingredient (API), novel salt forms, or improved synthesis intermediates or processes.
Comparative Analysis of Risperidone Patenting Strategies:
The patenting strategy for Risperidone, including the assertion of process patents like U.S. Patent 5,464,632, is a common approach in the pharmaceutical industry.
-
Process Patents vs. Composition of Matter Patents: Composition of matter patents provide the broadest protection, covering the molecule itself. Process patents protect the method of making the molecule. While a composition of matter patent is in force, a process patent might offer less immediate strategic advantage. However, once the composition patent expires, a strong process patent can still prevent competitors from using the most efficient or cost-effective manufacturing routes, thereby maintaining a competitive edge or facilitating licensing agreements.
-
Formulation Patents: These patents protect specific ways the drug is delivered to the patient (e.g., extended-release tablets, injectables). They are crucial for "evergreening" and can extend market exclusivity beyond the initial composition of matter patent. For Risperidone, innovations in long-acting injectables and orally disintegrating tablets were significant.
-
Polymorph Patents: Different crystalline forms (polymorphs) of a drug can have different physical properties, such as solubility and bioavailability. Patents on specific, therapeutically advantageous polymorphs can provide an additional layer of protection.
U.S. Patent 5,464,632, as a process patent, played a role in protecting the manufacturing of Risperidone during a period when other patents might have been expiring or were less comprehensive. Its expiration allowed for broader generic entry based on alternative manufacturing methods, while the market remained influenced by any remaining active patents on formulations or specific polymorphic forms.
Key Takeaways
U.S. Patent 5,464,632 protected a specific synthetic process for Risperidone, expiring in 2012. Its claims were directed at a particular chemical reaction pathway, intermediate compounds, and process conditions. The patent's expiration facilitated generic competition by allowing manufacturers to employ alternative synthesis methods. The broader Risperidone patent landscape has been characterized by innovator strategies to extend market exclusivity through patents on formulations, delivery systems, and potentially new uses, alongside ongoing litigation and generic entry.
FAQs
-
What is the primary significance of U.S. Patent 5,464,632 for generic drug manufacturers?
The primary significance of U.S. Patent 5,464,632 for generic drug manufacturers was that its expiration on November 7, 2012, removed a barrier to entry. It allowed generic companies to utilize the patented synthetic process or develop their own processes without infringing this specific patent, contributing to the availability of more affordable generic Risperidone.
-
Did U.S. Patent 5,464,632 claim the Risperidone molecule itself?
No, U.S. Patent 5,464,632 did not claim the Risperidone molecule as a composition of matter. Its claims were specifically focused on a novel process for preparing Risperidone, including specific reaction steps and intermediate compounds.
-
Can a generic manufacturer still be sued for patent infringement related to Risperidone even after U.S. Patent 5,464,632 expired?
Yes. The expiration of U.S. Patent 5,464,632 does not preclude patent infringement lawsuits related to other active patents covering Risperidone. These could include patents on different manufacturing processes, specific formulations (e.g., extended-release or injectable forms), specific polymorphic forms of the drug, or methods of medical treatment.
-
What are examples of "evergreening" strategies used by pharmaceutical companies that might apply to Risperidone?
For Risperidone, "evergreening" strategies likely included obtaining patents on new drug delivery systems, such as long-acting injectable formulations (e.g., Risperdal Consta) and orally disintegrating tablets. Patents on novel formulations or polymorphic forms can extend market exclusivity beyond the original composition of matter patent.
-
How did U.S. Patent 5,464,632 contribute to the overall market exclusivity of Risperidone?
U.S. Patent 5,464,632 contributed to market exclusivity by protecting a specific, likely efficient, manufacturing route for Risperidone. While composition of matter patents provide the broadest protection, process patents like this one can deter competitors from using that particular synthesis method, even if other methods exist, especially in the period leading up to and immediately following the expiration of primary patents.
Citations
[1] U.S. Patent 5,464,632. (1995). Process for the preparation of 1-[4-(4-fluorophenyl)-1-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4-phenylbutyl]-4-piperidinyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
